Therapeutic innovation has reshaped the dermatology landscape, expanding treatment options for chronic inflammatory dermatoses such as psoriasis, atopic dermatitis, vitiligo, chronic hand eczema, and hidradenitis suppurativa. Yet for many late-stage development programs, the central challenge is no longer whether a therapy can produce a short-term response. It is whether that response lasts, whether the safety profile can... The post Designing Dermatology Trials for Durable Disease Control appeared first on Premier Research .